Mesoblast Limited (NASDAQ: MESO) announced 36-month follow-up results from the 400-subject Phase 3 trial of its allogeneic cell therapyrexlemestrocel-L in patients with chronic low back pain (CLBP) associated with degenerative disc disease (DDD).
The data showed a durable reduction in back pain lasting at least three years from a single intra-discal injection of rexlemestrocel-L+hyaluronic acid (HA) carrier.
Related: FDA's Office Agrees On 12-Month Reduction In Pain As Primary Endpoint For Mesoblast's Back Pain Study.
Durable reduction in pain was most significant in the pre-specified population with CLBP of shorter duration than the study median of 68 months (n=194).
Pain reduction through 36 months was also seen in the subset of patients using opioids at baseline (n=168). The rexlemestrocel-L+HA group had a substantially greater reduction at all time points than saline controls.
Among patients on opioids at baseline, despite instructions to maintain existing therapies throughout the trial, at 36 months, 28% who received rexlemestrocel-L + HA were not taking an opioid compared with 8% of saline-treated controls.
Price Action: MESO shares traded 2.58% higher at $4.77 premarket on Wednesday.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.